Bart Barlogie, M.D., Ph.D.


Professor of Medicine and Pathologybart1

Tommy May Chair in Oncology
Director, Myeloma Institute

M.D. Heidelberg University, University of Munich
Ph.D. Max Planck Institute for Medical Research
Residency (internal medicine, hematology and infectious diseases, rheumatology, nephrology, cardiology, gastroenterology), University of Muenster.
Clinical Fellowship (oncology), M.D. Anderson Hospital and Tumor Institute.

Numerous Professional Appointments at M.D. Anderson, including:

Professor of Medicine, Department of Hematology

Professor of Pathology, Department of Pathology

Chief, Section of Experimental Therapeutics, Department of Hematology

Chief, Cytometry Center, Department of Hematology

Honors and Awards:

Distinguished Alumnus Award – UT MD Anderson Cancer Center – 1998

Jan Waldenstrom Award for Myeloma Research – 1999

Celgene Career Achievement Award in Hematology Research – 2002

Robert A. Kyle Lifetime Achievement Award,
International Myeloma Foundation – 2004

National Physician of the Year Award for Clinical Excellence,
Castle Connolly Medical Ltd., 2006

Society Memberships:

American Society for Clinical Investigation

American Society of Clinical Oncology

American Society of Hematology

Association of American Physicians

International Society of Hematology

The American Society for Bone and Mineral Research

 About Dr. Barlogie

Bart Barlogie, M.D., Ph.D., professor of medicine and pathology at the University of Arkansas for Medical Sciences (UAMS) in Little Rock, is the director of the UAMS Myeloma Institute for Research and Therapy.

Dr. Barlogie is an internationally recognized authority on the use of novel therapies to combat multiple myeloma for improved patient outcome. On the faculty at UAMS since 1989, Dr. Barlogie has built the largest center in the world devoted exclusively to clinical care for and research in multiple myeloma. More than 9,000 patients from every state in the U.S. and more than 50 countries have come to the Myeloma Institute.

With a keen insight into the biology of myeloma, Dr. Barlogie pioneered the use of tandem peripheral stem cell transplant for multiple myeloma. Other firsts under Dr. Barlogie’s leadership include performing transplants on an outpatient basis, safely transplanting patients age 70 and older, transplanting patients with renal disease, and introducing thalidomide as anti-angiogenesis therapy. Dr. Barlogie’s Total Therapy approach, by which multiple agents are provided upfront, has continually increased median survival, with a projected median survival of 15 years for patients enrolled in the third Total Therapy protocol.

Dr. Barlogie has successfully secured National Cancer Institute funding for his translational research program project, Growth Control of Multiple Myeloma, for 20 consecutive years.

A consummate clinician scientist, Dr. Barlogie has authored more than 544 papers in prestigious journals such as Blood, New England Journal of Medicine, Journal of Clinical Oncology, British Journal of Haematology, and Cancer. He has more than595 abstracts and 75 book chapters to his credit, and serves on the editorial board of numerous journals.

Dr. Barlogie received his M.D. from the University of Heidelberg and completed his medical training at the Universities of Munich and Muenster. He earned his Ph.D. at the Max Planck Institute for Medical Research. Dr. Barlogie was at M.D. Anderson Cancer Center prior to joining the UAMS faculty.